Does Dr. RAJAN AGARWAL have financial conflicts of interest?

Dr. RAJAN AGARWAL (MD) has received a total of $3,136,880 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $981,539 in personal promotional payouts (consulting, meals, travel) and $2,155,340 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. RAJAN AGARWAL?

According to CMS Open Payments data, Dr. RAJAN AGARWAL received funding from E.R. SQUIBB & SONS, L.L.C ($1,760,932), MERCK SHARP & DOHME CORPORATION ($858,589), and REGENERON PHARMACEUTICALS ($172,639).

Does Dr. RAJAN AGARWAL receive research grants or speaking fees?

Dr. RAJAN AGARWAL has received $981,539 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $2,155,340 in clinical research grants.

DR. RAJAN AGARWAL

MDReal-Time Hydrated

Specialty: Radiology, Diagnostic Radiology

Practice Location: ABINGTON, PA 19001

NPI Number: 1871642017

LIFETIME INDUSTRY VALUE

$3,136,880

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. AGARWAL is a verified Radiology, Diagnostic Radiology practitioner based in ABINGTON, PA.

Between 2021 and 2024, Dr. AGARWAL had an overall industry promotional and research financial footprint of $3,136,880 as recorded in the federal CMS Open Payments database.

$981,539 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$2,155,340 was allocated to sponsored clinical trials and medical research activities.

Dr. AGARWAL's primary funding source is E.R. SQUIBB & SONS, L.L.C, which accounts for $1,760,932 (representing 56.1% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

E.R. SQUIBB & SONS, L.L.C

Rank 1

$1,760,932

56.1%

MERCK SHARP & DOHME CORPORATION

Rank 2

$858,589

27.4%

REGENERON PHARMACEUTICALS

Rank 3

$172,639

5.5%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.